Who is sponsoring NCT04542616?

NCT04542616 is sponsored by State University of New York at Buffalo.

What drugs are being tested in NCT04542616?

Interventions in NCT04542616: Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation.

Is NCT04542616 still recruiting?

NCT04542616 is currently completed. Last updated 17 April 2026.

Are results published for NCT04542616?

Yes — primary outcome results have been posted to ClinicalTrials.gov. See the outcomes section above for details.

Last reviewed 2026-04-17 · How we verify

NCT04542616: B350vsCP250

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Baerveldt 350 vs Ahmed ClearPath 250 for the Treatment of Glaucoma

Completed NA Results posted Last updated 17 April 2026

What this trial tests

NA trial testing Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation in Glaucoma in 80 participants. Completed in 31 July 2024.

Timeline

13 August 2020

Primary endpoint
31 July 2024

31 July 2024

Quick facts

Lead sponsor	State University of New York at Buffalo
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	single
Primary purpose	treatment
Enrollment	80
Start date	13 August 2020
Primary completion	31 July 2024
Estimated completion	31 July 2024
Sites	1 location across United States

Drugs / interventions tested

Baerveldt 350 vs. Ahmed ClearPath 250 tube shunt implantation

Conditions studied

Glaucoma — all drugs for Glaucoma →

Sponsor

State University of New York at Buffalo

Who can join

18 and older, any sex, with Glaucoma. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Intraocular Pressure (IOP) Primary · Baseline, Month 1, Month 3, Month 6, Month 12, Month 24

Mean IOP in each treatment group at the above time points

Baseline

Group	Value	95% CI
Baerveldt 350	22.58	± 8.62
Ahmed ClearPath 250	20.95	± 7.00

Month 1

Group	Value	95% CI
Baerveldt 350	15.0	± 4.8
Ahmed ClearPath 250	15.1	± 4.8

Month 3

Group	Value	95% CI
Baerveldt 350	11.7	± 4.7
Ahmed ClearPath 250	12.1	± 4.3

Month 6

Group	Value	95% CI
Baerveldt 350	11.3	± 4.3
Ahmed ClearPath 250	12.2	± 5.3

Month 12

Group	Value	95% CI
Baerveldt 350	10.0	± 3.7
Ahmed ClearPath 250	12.0	± 4.4

Month 24

Group	Value	95% CI
Baerveldt 350	10.9	± 4.0
Ahmed ClearPath 250	13.6	± 3.7

Adverse events — posted to ClinicalTrials.gov

Time frame: 24 months. Reporting threshold: 0%. Adverse-event reports describe events observed during the trial — not all are caused by the drug.

Baerveldt 350

Serious: 1/38 (3%)

Deaths: 1/38

Ahmed ClearPath 250

Serious: 1/40 (3%)

Deaths: 1/40

Serious adverse events (1 terms)

Reaction	System	Baerveldt 350	Ahmed ClearPath 250
Myocardial Infarction/Cardiac Arrest (heart attack)*	Cardiac disorders	—	—

Other adverse events (1 terms — click to expand)

Reaction	System	Baerveldt 350	Ahmed ClearPath 250
Surgical failure	Surgical and medical procedures	—	—

Most-reported serious reactions: Myocardial Infarction/Cardiac Arrest (heart attack)*.

Data from ClinicalTrials.gov NCT04542616 adverse events section.

Sponsor's own description

To compare the safety and efficacy of Baerveldt 350 and Ahmed ClearPath 250 tube shunts in lowering IOP in glaucoma patients.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other State University of New York at Buffalo trials

Trials by the same sponsor.

NCT07072767 — Hybrid Dissemination Study of A Digital-Analog Intervention to Increase Live Donor Kidney Transplantation · NA · not yet recruiting
NCT07140848 — CGM-Enhanced DPP to Prevent Type 2 Diabetes in Adults With Prediabetes · NA · not yet recruiting
NCT07433959 — Neuromodulation to Improve Grasping Function After SCI · NA · not yet recruiting
NCT07403539 — Speech Learning and Speech Production in Parkinson's Disease · NA · recruiting
NCT05367362 — Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute · Phase 2 · withdrawn

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04542616 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by State University of New York at Buffalo
Last refreshed: 17 April 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04542616.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing